MNKKQ Stock Recent News

SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Mallinckrodt Securities Litigation: UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY BARBARA STROUGO, Individually and on Behalf of All Others Similarly Situated,   No. 3:20-cv-10100-RK (TJB)         Plaintiff, CLASS ACTION     vs. SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION       MALLINCKRODT PUBLIC LIMITED COMPANY, et al.,       Defendants.     TO.

–  The INOmax EVOLVE DS is our next-generation nitric oxide delivery system that combines mini-cylinder technology, automation, integration, and interaction into one device1 – – The INOmax EVOLVE DS is now available for contracting and distribution for use in U.S. hospitals – DUBLIN , Oct. 10, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced the rollout of the U.S. Food and Drug Administration (FDA) cleared INOmax® EVOLVE™ DS delivery system for the delivery of INOmax® (nitric oxide) gas, for inhalation. This nationwide rollout follows the successful introduction of the INOmax EVOLVE DS Pilot program.

DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it will report second quarter 2022 earnings results for the period ended July 1, 2022, on Thursday, August. 11, 2022.  A conference call for investors will begin at 8:30 a.m.